ReShape Lifesciences Announces Distribution in Australia
ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.
The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.
Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.
About ReShape Lifesciences Inc
Lifesciences™ (OTCQB: RSLS) is a medical device company
focused on technologies to treat obesity and metabolic
diseases. The FDA-approved LAP-BAND® Adjustable Gastric
Banding System is designed to provide minimally invasive
long-term treatment of severe obesity and is an alternative
to more invasive surgical stapling procedures such as
gastric bypass or sleeve gastrectomy. The ReShape Vest™
System is an investigational, minimally invasive,
laparoscopically implanted medical device that wraps around
the stomach, emulating the gastric volume reduction effect
of conventional weight-loss surgery. It is intended to
enable rapid weight loss in obese and morbidly obese
patients without permanently changing patient